ATE162079T1 - Verwendung von antikörper enthaltenden präparationen zur immunsuppression - Google Patents

Verwendung von antikörper enthaltenden präparationen zur immunsuppression

Info

Publication number
ATE162079T1
ATE162079T1 AT92117775T AT92117775T ATE162079T1 AT E162079 T1 ATE162079 T1 AT E162079T1 AT 92117775 T AT92117775 T AT 92117775T AT 92117775 T AT92117775 T AT 92117775T AT E162079 T1 ATE162079 T1 AT E162079T1
Authority
AT
Austria
Prior art keywords
immunosupression
preparations containing
containing antibodies
preparations
antibodies
Prior art date
Application number
AT92117775T
Other languages
German (de)
English (en)
Inventor
Margot Zoeller
Peter Herrlich
Helmut Ponta
Original Assignee
Kernforschungsz Karlsruhe
Deutsches Krebsforsch
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kernforschungsz Karlsruhe, Deutsches Krebsforsch, Boehringer Ingelheim Int filed Critical Kernforschungsz Karlsruhe
Application granted granted Critical
Publication of ATE162079T1 publication Critical patent/ATE162079T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92117775T 1991-10-23 1992-10-17 Verwendung von antikörper enthaltenden präparationen zur immunsuppression ATE162079T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4134982A DE4134982A1 (de) 1991-10-23 1991-10-23 Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression

Publications (1)

Publication Number Publication Date
ATE162079T1 true ATE162079T1 (de) 1998-01-15

Family

ID=6443260

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92117775T ATE162079T1 (de) 1991-10-23 1992-10-17 Verwendung von antikörper enthaltenden präparationen zur immunsuppression

Country Status (17)

Country Link
US (1) US5951982A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0538754B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH05310596A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100252620B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE162079T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU659687B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2081150C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE4134982A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0538754T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2111031T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3026526T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU216020B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL103510A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO311965B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ244851A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW273514B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA928162B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589458A (en) * 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
EP0703989B1 (en) 1993-06-18 1997-11-05 Oy Biotie Therapies COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
DE4431297A1 (de) * 1994-09-02 1996-03-07 Boehringer Ingelheim Int Monoklonaler Antikörper gegen CD44v6
DE19540515C1 (de) * 1995-10-31 1997-02-06 Boehringer Ingelheim Int Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
WO1997030173A1 (fr) * 1996-02-15 1997-08-21 Chugai Seiyaku Kabushiki Kaisha Anticorps monoclonal reconnaissant les antigenes presents a la surface des cellules endotheliales d'un vaisseau tumoral
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
DE19652815C2 (de) * 1996-12-18 1999-11-11 Karlsruhe Forschzent Mittel zur Identifizierung und Therapie metastasierender Tumore
DE19653607A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
IL121656A0 (en) * 1997-08-29 1998-02-08 Yissum Res Dev Co Diagnosis prevention and treatment of diabetes
US7534605B2 (en) 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
WO2004024750A2 (en) * 2002-09-13 2004-03-25 Dyax Corporation Cd44-binding ligands
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US20070280930A1 (en) * 2004-03-17 2007-12-06 Kasper Mathias Antoon Rouschop Cd44-Targeting for Reducing/Preventing Ischemia-Reperfusion-Injury
CA2620306A1 (en) 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
EP2197491A4 (en) 2007-09-04 2011-01-12 Univ California HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
US10517969B2 (en) 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
BR112012012887A2 (pt) 2009-12-02 2017-05-02 Imaginab Inc minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito.
DK2886126T3 (en) 2013-12-23 2017-09-18 Exchange Imaging Tech Gmbh Nanoparticle conjugated to CD44-binding peptides
ES2799404T3 (es) 2014-07-15 2020-12-17 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd Polipéptidos de CD44 aislados y usos de los mismos
JP7026613B2 (ja) 2015-08-07 2022-02-28 イマジナブ・インコーポレーテッド 標的分子に対する抗原結合コンストラクト
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US11313243B2 (en) 2018-07-12 2022-04-26 Rolls-Royce North American Technologies, Inc. Non-continuous abradable coatings

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114478T1 (de) * 1987-08-11 1994-12-15 Univ Leland Stanford Junior Verfahren zur kontrolle der leukozyten- extravasation.
DE4014510A1 (de) * 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
CA2059824A1 (en) * 1991-02-26 1992-08-27 Thomas M. Aune Hybridomas and monoclonal antibodies that inhibit anti-cd3-stimulated t cell proliferation
EP0703989B1 (en) * 1993-06-18 1997-11-05 Oy Biotie Therapies COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6

Also Published As

Publication number Publication date
JPH05310596A (ja) 1993-11-22
CA2081150A1 (en) 1993-04-24
DE59209129D1 (de) 1998-02-19
HU216020B (hu) 1999-04-28
ES2111031T3 (es) 1998-03-01
EP0538754B1 (de) 1998-01-14
EP0538754A3 (en) 1994-05-25
ZA928162B (en) 1993-05-05
DK0538754T3 (da) 1998-03-30
DE4134982A1 (de) 1993-04-29
EP0538754A2 (de) 1993-04-28
AU659687B2 (en) 1995-05-25
GR3026526T3 (en) 1998-07-31
HUT63063A (en) 1993-07-28
TW273514B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1996-04-01
CA2081150C (en) 2001-04-10
NO924103L (no) 1993-04-26
IL103510A0 (en) 1993-03-15
NO924103D0 (no) 1992-10-22
AU2724492A (en) 1993-04-29
NO311965B1 (no) 2002-02-25
US5951982A (en) 1999-09-14
KR100252620B1 (ko) 2000-09-01
NZ244851A (en) 1997-07-27
KR930007460A (ko) 1993-05-20

Similar Documents

Publication Publication Date Title
ATE162079T1 (de) Verwendung von antikörper enthaltenden präparationen zur immunsuppression
US5260274B1 (en) Factor VIII binding domain of von willebrand factor
DE69128516D1 (de) Neue Mercaptoacetylamid-Derivate zur Verwendung als Enkephalinase- und ACE-Hemmer
FI931708A0 (fi) Herbicida substituerade aryl-haloalkylpyrazoler
ATE125269T1 (de) Radiomarkierte peptide mit antikoagulanswirkung.
DE68918217D1 (de) Familie von modifizierten Antikörpern mit hoher Affinität zur Behandlung von Krebs.
DE59400013D1 (de) Verfahren zur Herstellung von Methylchlorsilanen.
AU7657387A (en) Apoprotein b-100 specific monoclonal antibodies
EP0330521A3 (en) Antihypertensive hyperimmune milk
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
DE59308715D1 (de) Verfahren zur Herstellung von Dimethylchlorsilan
ES2043707T3 (es) 1-sila-2-azaciclopentanos n-silil sustituidos.
DE3877015D1 (de) Antikoerper enthaltende stabilisierte waesserige zusammensetzung.
DE59004279D1 (de) Verfahren zur C-terminalen Modifizierung von Proteinen.
DE69328798D1 (de) Verfahren zur Herstellung von 3-Hydroxymethyl-1-propargyl-imidazolidin-2,4-dion
ATE136884T1 (de) Neue 2-mercaptomethylen-tetrahydronaphthalin- und -indan-2-carboxamide als enkephalinaseinhibitoren
ATA251487A (de) Windsichter zur sichtung von schuettguetern feinster koernung
DE69201818D1 (de) Verfahren zur linearen Dikarbonylierung von difunktionellisierten Butenen.
DE69329255D1 (de) Verfahren zur Herstellung von 1-Propargylimidazolidin-2,4-Dion
FI895269A0 (fi) Ljustraolning alstrande anordning foer bioanalyser.
DK349787A (da) 1,2,3-thiadiazol-4-thiolater samt n3-thioacylsemicarbazider
GR3018066T3 (en) Schizosaccharomyces specific polypeptide.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee